These Analysts Cut Their Forecasts On Liquidia
Portfolio Pulse from Avi Kapoor
Liquidia Corporation (NASDAQ:LQDA) received tentative FDA approval for YUTREPIA, a treatment for pulmonary hypertension, but faces regulatory exclusivity challenges from United Therapeutics' Tyvaso DPI. Liquidia's stock fell 30.6% following the news, and analysts have lowered their price targets while maintaining Buy ratings.
August 20, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Liquidia's YUTREPIA received tentative FDA approval but faces a regulatory exclusivity challenge from United Therapeutics' Tyvaso DPI, delaying final approval until May 2025. The stock dropped 30.6%, and analysts lowered price targets while maintaining Buy ratings.
The tentative FDA approval is overshadowed by the exclusivity granted to Tyvaso DPI, delaying YUTREPIA's market entry until 2025. This regulatory hurdle led to a significant stock price drop. Analysts' lowered price targets reflect the impact, though they maintain a positive long-term outlook with Buy ratings.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100